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Abstract
Background: In prostate cancer, the identification of drug combinations that could reduce the
tumor cell population and rapidly eradicate hormone-resistant cells potentially present would be a
remarkable breakthrough in the treatment of this disease.
Methods: The study was performed on a hormone-sensitive prostate cancer cell line (LNCaP)
grown in normal or hormone-deprived charcoal-stripped (c.s.) medium. Cell viability and apoptosis
were assessed by SRB assay and Annexin-V/TUNEL assays, respectively. Activated caspase-3, p21,
pMEK and MCL-1 expression levels were detected by western blotting.
Results: The simultaneous exposure of zoledronic acid [100 μM] and docetaxel [0.01 μM] for 1 h
followed by treatment with zoledronic acid for 72, 96 or 120 h produced a high synergistic
interaction (R index = 5.1) with a strong decrease in cell viability. This cytotoxic effect was
associated with a high induction of apoptosis in both LNCaP and in c.s. LNCaP cells. The induction
of apoptosis was paralleled by a decrease in pMEK and Mcl-1 expression.
Conclusion: The zoledronic acid-docetaxel combination produced a highly significant synergistic
effect on the LNCaP cell line grown in normal or hormone-deprived medium, the principal
molecular mechanisms involved being apoptosis and decreased pMEK and Mcl-1 expression. This
experimentally derived schedule would seem to prevent the selection and amplification of
hormone-resistant cell clones and could thus be potentially used alongside standard androgen
deprivation therapy in the management of hormone-sensitive prostate carcinoma.
Introduction
The overall incidence of prostate cancer, one of the most
common lethal malignancies and the second cause of can-
cer mortality in males, is gradually increasing in western
countries. In the early stages of the disease, surgery, radio-
therapy and/or androgen deprivation are the most effec-
tive clinical therapies. In particular, hormonal therapy
leads to remission which typically lasts from 2 to 3 years.
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However, prostate cancer frequently metastasizes to bone
and almost invariably progresses to an androgen-inde-
pendent state, with a poor prognosis and a median sur-
vival that varies from 10 to 20 months [1].
Notwithstanding the introduction of new chemothera-
peutic agents, the life expectancy of patients with
advanced prostate cancer is still limited. The development
of new drugs or the identification of novel drug combina-
tions which could reduce the development of endocrine-
refractory cell clones thus remain important goals.
It has been shown that docetaxel (Doc) exerts a potent
cytotoxic effect in vitro and considerably prolongs survival
in patients with advanced prostate cancer [2,3]. At the
same time, zoledronic acid (Zol) has proven to be capable
of preventing tumor growth in different in vitro models [4]
and has shown significant clinical potential for reducing
cancer-related bone lesions and inhibiting bone re-
absorption [5].
The Ras/Raf/MEK/ERK signalling cascade is one of the
most important intracellular pathways controlling cell
proliferation, differentiation and cell death, and appears
to be involved in prostate cancer drug resistance [6,7].
Moreover, in different experimental models, it has been
shown that inhibition of at least one of these regulatory
proteins may induce apoptosis through the downregula-
tion of the anti-apoptotic protein Mcl-1, a member of the
Bcl-2 family [8,9]. Mcl-1 is expressed in a fairly high per-
centage of prostate tumors [10-12], and the inhibition of
Ras/Raf/MEK/ERK-mediated signals, and consequently of
Mcl-1 expression, could therefore also be a key objective
in the treatment of hormone-sensitive prostate cancer
cells, as shown by Cavarretta et al [13].
The aim of the present study was to examine the in vitro
activity of Zol and low Doc concentrations, alone or in
combination, and to explore the molecular mechanisms
underlying treatment-related cell proliferation and apop-
tosis, especially in relation to MEK and Mcl-1 expression.
Very low Doc concentrations were chosen so as not to pre-
clude the use of the taxane at conventional doses as sec-
ond-line treatment in more advanced disease. Moreover,
in order to approximate clinical conditions, the study was
performed on cells grown in normal or hormone-
deprived medium and on the same cell line after pretreat-
ment with the taxane.
Materials and methods
Cell culture
The studies were performed on a hormone-sensitive pros-
tate cancer cell line, LNCaP, obtained from the American
Type Culture Collection (Rockville, MD). The cell line was
maintained as a monolayer at 37°C and subcultured
weekly. Culture medium was composed of RPMI 1640
supplemented with 10% fetal calf serum and 1%
glutamine (Mascia Brunelli s.p.a., Milan, Italy). Cells were
used in the exponential growth phase in all the experi-
ments. Depending on the experimental setting, LNCaP
cells were seeded in RPMI 1640 medium containing either
10% fetal calf serum or charcoal-stripped 10% fetal calf
serum. Doc pre-treated LNCaP cells were generated by
exposing the cell line to 0.001 μM of Doc for 1 h once a
week for one month, which produced cells resistant to this
dose of taxane. Thereafter, these cells were maintained in
culture medium containing 0.001 μM of the taxane.
Drugs
Docetaxel (Taxotere®), kindly supplied by Aventis
Pharma, was solubilized and stored at a concentration of
12.6 mM in 13% ethanol at 4°C and diluted in medium
before use. The final concentration of ethanol never
exceeded 0.01% and therefore had no effect on cell
growth or viability. Control cells were exposed to the
same amount of solvent. Zoledronic acid (Zometa®)
(Zol), kindly provided by Novartis, was solubilized and
stored at a concentration of 25 mM in sterile water at -
20°C and diluted in medium before use.
Chemosensitivity assay
Sulforhodamine B (SRB) assay was used according to the
method by Skehan et al. [14]. Briefly, cells were collected
by trypsinization, counted and plated at a density of 5,000
cells/well in 96-well flat-bottomed microtiter plates (100
μl of cell suspension/well). In the chemosensitivity assay,
experiments were run in octuplicate, and each experiment
was repeated three times. The optical density (OD) of cells
was determined at a wavelength of 540 nm by a colori-
metric plate reader. Growth inhibition and cytocidal effect
of drugs were calculated according to the formula
reported by Monks et al [15]: [(ODtreated - ODzero)/(ODcon-
trol - ODzero)] × 100%, when ODtreated is > to ODzero. If
ODtreated is above ODzero, treatment has induced a cyto-
static effect, whereas if ODtreated is below ODzero, cell kill-
ing has occurred. The ODzero depicts the cell number at the
moment of drug addition, the ODcontrol reflects the cell
number in untreated wells and the ODtreated reflects the
cell number in treated wells on the day of the assay.
Single drug exposure
Cells were exposed for 1 h to 0.001-, 0.01-, 0.1- or 1.0-μM
concentrations of Doc followed by a 72-, 96- or 120-h cul-
ture in drug-free medium. Zol treatment consisted of con-
tinuous exposure of 50-, 100-, or 200-μM concentrations
for 72, 96 or 120 h.
Drug combinations
The following treatment schedules were utilized (Table 1):Journal of Translational Medicine 2008, 6:43 http://www.translational-medicine.com/content/6/1/43
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1. Simultaneous exposure to Zol 100 μM and Doc 0.001,
0.01 or 0.1 μM for 1 h followed by Zol exposure for 72, 96
or 120 h;
2. Continuous exposure to Zol for 72, 96 or 120 h fol-
lowed by simultaneous exposure to Zol 100 μM and Doc
0.001, 0.01 or 0.1 μM for 1 h.
Cytotoxic activity was evaluated immediately after the end
of drug exposure.
Drug interaction analysis
Kern et al.'s method [16], subsequently modified by
Romanelli et al. [17], was used to evaluate the interaction
between drugs. In brief, the expected cell survival (Sexp,
defined as the product of the survival observed with drug
A alone and the survival observed with drug B alone) and
the observed cell survival (Sobs) for the combination of A
and B were used to construct an R index (RI): RI = Sexp/
Sobs. An RI of ≤ 0.5 indicated the absence of synergism or
antagonism. Synergism was defined as any value of RI >
1.5. In all experiments, the standard deviation did not
exceed 10%. Therefore, only differences of ≥ 0.5 from
unity in RI values were considered significant.
Flow cytometry
After different drug exposures, medium was removed and
cells were detached from the flasks by trypsin treatment,
washed twice with PBS and stained according to the differ-
ent methods specified below. Flow cytometric analysis
was performed using a FACS Canto flow cytometer (Bec-
ton Dickinson, San Diego, CA). Data acquisition and
analysis were performed using FACSDiva software (Bec-
ton Dickinson). Samples were run in triplicate and 10,000
events were collected for each replica. Data were the aver-
age of three experiments, with errors under 5%.
Apoptosis
TUNEL assay
Cells were fixed in 1% paraformaldehyde in PBS on ice for
15 min, suspended in ice cold ethanol (70%) and stored
overnight at -20°C. Cells were then washed twice in PBS
and resuspended in PBS containing 0.1% Triton X-100 for
5 min at 4°C. Thereafter, samples were incubated in 50 μl
of solution containing TdT and FITC-conjugated dUTP
deoxynucleotides 1:1 (Roche Diagnostic GmbH, Man-
nheim, Germany) in a humidified atmosphere for 90 min
at 37°C in the dark, washed in PBS, counterstained with
propidium iodide (2.5 μg/ml, MP Biomedicals, Verona,
Italy) and RNAse (10 Kunits/ml, Sigma Aldrich, Milan,
Italy) for 30 min at 4°C in the dark and analyzed by flow
cytometry.
Annexin-V assay
Cells were harvested, washed once in PBS and incubated
with 10 μl/ml Annexin V-FITC in binding buffer (Bender
MedSystems, Vienna, Austria) for 15 min at 37°C in a
humidified atmosphere in the dark. Cells were then
washed in PBS and suspended in binding buffer. Immedi-
ately before flow cytometric analysis, propidium iodide
was added to a final concentration of 5 μg/ml to distin-
guish between total apoptotic cells (Ann-V + and PI - or +)
and necrotic cells (Ann-V - and PI +). For each sample,
15,000 events were recorded.
Western blot
Cells were lysed and proteins were denaturated, separated
on 10% SDS-polyacrylamide gel and electroblotted onto
Hybond-C extra membrane (Amersham Pharmacia Bio-
tech, Cologna Monzese, Italy). The membrane was
stained with Ponceau S (Sigma Aldrich) to verify equal
amounts of sample loading and then incubated for 2 h at
room temperature with T-PBS 5% non fat dry milk. The
membrane was probed overnight at 4°C with the anti-
body, after which horseradish peroxidise-conjugated sec-
ondary antibody diluted 1:1,000 (Dako Corporation,
Glostrup, Denmark) was added. Bound antibodies were
detected by enhanced chemiluminescence (ECL) using an
ECL kit (Amersham Pharmacia Biotech). The following
primary antibodies were used: p21 (monoclonal anti-
body, dilution 1:250) (BioOptica, Milan, Italy), caspase-3
(polyclonal antibody, dilution 1:500) (Cell Signalling
Technology, Inc., Beverly, MA), pMEK (monoclonal anti-
body, dilution 1:1000) (Cell Signalling Technology),
actin (polyclonal antibody, dilution 1:5000) (Sigma
Aldrich) and Mcl-1 (monoclonal antibody, dilution
1:100) (BD, Pharmingen, San Diego, CA). Quantitative
analysis was carried out with Quantiscan software (Bio-
soft, Cambridge, UK).
Morphological investigation
After different drug exposures, medium was removed,
cells were detached from the flasks by trypsin treatment,
washed twice with PBS, fixed in ethanol (70%), stained
with the cell-permeable dyes 4',6-DAPI (Molecular
Probes, Leiden, The Netherlands) and SRB (Sigma
Aldrich) and then examined by fluorescence photomicro-
scope (Zeiss, Axioscope 40) to visualize chromatin con-
densation and/or fragmentation typical of apoptotic cells.
Statistical analysis
Differences between treatments, in terms of dose response
and apoptosis, were determined using the Student's t test
Table 1: Treatment schedules in LNCaP hormone-sensitive cell 
line
Doc* + Zol (100 μM) 1 h → Zol (100 μM) 72, 96, 120 h
Zol (100 μM) 72, 96, 120 h → Doc* + Zol (100 μM) 1 h
* 0.001, 0.01, or 0.1 μMJournal of Translational Medicine 2008, 6:43 http://www.translational-medicine.com/content/6/1/43
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Cytotoxicity was assessed at scalar drug concentrations
and after different exposure times. Doc produced a strong
cytotoxic effect after all treatment schedules and the 50%
lethal concentration (LC50) was reached 120 h after a 1-h
exposure to a 0.057-μM concentration. Although Zol
treatment also produced a cytotoxic effect, LC50 was only
reached after a 120-h exposure to a concentration of
176.70 μM (Figure 1).
Drug combinations
After preliminary experiments, the efficacy of two differ-
ent drug combination schedules was further explored
(Table 1). Simultaneous exposure to Zol (100 μM) and
Doc (0.001 μM) for 1 h followed by Zol exposure for 72,
96 or 120 h produced a strong cytocidal effect, and the
LC50 was reached after 96 h of continuous exposure (Fig-
ure 2A). At the higher Doc concentrations (0.01 and 0.1
μM), cytocidal activity further increased, exceeding the
LC90 (Figure 2B–C). Starting from a 0.01-μM Doc concen-
tration, the combination schedule produced an important
synergistic effect which yielded an R index of 5.1. The
highest Doc concentration (0.1 μM) did not produce any
further significant synergistic interactions and was there-
fore not tested in subsequent experiments. The schedule
consisting of Zol followed by simultaneous exposure to
Zol and Doc induced only a very weak additive effect with
respect to Zol used alone (Figure 2A–B–C).
Dose effect curves of Doc and Zol in LNCaP hormone-sensitive cell line Figure 1
Dose effect curves of Doc and Zol in LNCaP hormone-sensitive cell line. Net cell growth was measured by SRB assay 
at the end of different washout (w.o.) times after a 1-h exposure to scalar concentrations of Doc (0.01, 0.1, 1.0 μM – left dia-
gram) and after continuous exposure to scalar concentrations of Zol (50, 100, 200 μM – right diagram). Error bars represent 
the mean standard deviation.Journal of Translational Medicine 2008, 6:43 http://www.translational-medicine.com/content/6/1/43
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Apoptosis
Assessment of apoptosis by TUNEL assay showed that
low-dose Doc induced a small percentage of apoptotic
cells which never exceeded 10% at either the longest expo-
sure time (120 h) or the highest drug concentration (0.01
μM). Conversely, Zol 100 μM induced a statistically sig-
nificant, exposure time-dependent increment in apoptotic
cells between 4- and 20-fold higher than that detected in
untreated cells (Table 2).
The schedule using Doc 0.001 μM did not produce a sig-
nificantly higher number of apoptotic cells with respect to
treatment with Zol alone. Conversely, the drug combina-
tion using a 0.01-μM Doc concentration induced a signif-
icant increase in the percentage of TUNEL-positive cells
ranging from 40% at 72 h to 66% at 120 h (Table 2). Sim-
ilar results for the TUNEL assay were observed regardless
of the type of medium used and were confirmed by mor-
phological evaluation of cells exposed to the aforemen-
tioned treatments (Figure 3). Apoptosis evaluation by
ANN-V assay in the LNCaP line grown in different hor-
mone culture conditions showed that the number of
apoptotic cells progressively increased after Doc, Zol or
combined drug exposure from about 20 to 70% at any of
the times considered, and once again this increase was
Comparison between different drug schedules Figure 2
Comparison between different drug schedules. Dashed line: activity observed 72, 96 and 120 h after a 1-h exposure to 
low Doc concentrations (0.001, 0.01 and 0.1 μM in diagrams A, B and C, respectively). Solid line: activity detected after a 72-, 
96- and 120-h continuous exposure to Zol 100 μM. Dotted line: activity observed after a 1-h concomitant exposure to Zol 100 
μM and low Doc concentrations (0.001, 0.01 and 0.1 μM, in diagrams A, B and C, respectively) followed by prolonged expo-
sure to Zol 100 μM. Dash-dotted line: activity observed after prolonged exposure to Zol 100 μM followed by a 1-h concomi-
tant exposure to Zol 100 μM and low Doc concentrations (0.001, 0.01 and 0.1 μM, in diagrams A, B and C, respectively). Error 
bars represent the mean standard deviation.
Table 2: Apoptotic cells (%) in LNCaP line by TUNEL assay
Observation time
72 h 96 h 120 h
Control 1.5 2.0 2.0
Doc 1 h 0.001 μM1 . 3 1 . 1 4 . 8
0.01 μM2 . 5 3 . 8 9 . 2
Zol continuous
 exposure
100 μM 4.9 11.5 37.8*
Doc (0.001 μM) +
Zol (100 μM) 1 h → Zol (100 μM)
11.2 20.1 30.8*
Doc (0.01 μM) +
Zol (100 μM) 1 h → Zol (100 μM)
40.2 41.6 66.5*
*Significance at p < 0.05 by t testJournal of Translational Medicine 2008, 6:43 http://www.translational-medicine.com/content/6/1/43
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similar regardless of the type of medium used (Figure 4).
The number of apoptotic cells also showed a similar trend
in taxane pre-treated LNCaP cells, but reached a signifi-
cantly higher level (90%) after the drug sequence expo-
sures.
Interference in apoptosis- and cell proliferation-related 
markers
The expression of the pMEK protein kinase was progres-
sively downregulated from 2- to 10-fold by the bisphos-
phonate and completely disappeared after 96 h of
continuous exposure to the drug (Figure 5). Conversely, a
1-h treatment with Doc induced a 7-fold increase in pMEK
expression after 48 h, which then progressively decreased
and disappeared at 120 h. After the synergic drug
sequence exposure, a 4-fold increase in pMEK expression
with respect to the control was also observed, which, how-
ever, completely disappeared after 96 h.
The expression of Mcl-1 protein was downregulated up to
3- and 5-fold by Zol and Doc, respectively. However,
whilst these inhibiting effects persisted in the presence of
the bisphosphonate for up to 120 h, a 1.5-fold upregula-
tion of Mcl-1 was observed after treatment with the taxane
with respect to the control, showing a complementary
profile to that of pMEK. The drug sequence exposure not
only prevented the late upregulation observed after treat-
ment with Doc, but also induced the total disappearance
of Mcl-1 protein expression. No important variations in
pMEK or Mcl-1 expression with respect to the control were
observed after exposure times of < 48 h (data not shown).
Whilst p21 expression was not affected by exposure to
Zol, it increased up to 2-fold after Doc treatment. Con-
versely, p21 expression showed a > 1.5-fold decrease after
120 h of the combination treatment.
The active form of caspase-3 was detected around 120 h
after bisphosphonate exposure, whereas it was observed
earlier and at lower levels after Doc treatment. Conversely,
after the drug sequence exposure, its expression profile
was quantitatively and qualitatively the sum of the expres-
sion detected after exposure to the single drugs.
All the aforementioned alterations in marker expression
were observed regardless of the type of medium used.
Discussion
In the present study, docetaxel and zoledronic acid
induced noteworthy cytostatic and cytocidal effects on the
hormone-sensitive prostate cancer cell line, LNCaP, in
agreement with results from previous papers [18-21]. In
Representative cytofluorimetric dot plots of one of the TUNEL experiments and characteristic morphologic images of apop- totic cells observed after drug exposure Figure 3
Representative cytofluorimetric dot plots of one of the TUNEL experiments and characteristic morphologic 
images of apoptotic cells observed after drug exposure. A and E, untreated cells; B and F, after a 1-h exposure to Doc 
0.01 μM followed by a 120-h w.o.; C and G, after a 120-h continuous exposure to Zol 100 μM; D and H, after exposure to the 
combination Doc + Zol → Zol.Journal of Translational Medicine 2008, 6:43 http://www.translational-medicine.com/content/6/1/43
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particular, the highest inhibition of cell proliferation was
observed after Doc exposure and was already evident at
concentrations 200-fold lower than the plasma peak level.
Interestingly, among the different drug schedules tested, a
short, concomitant exposure to Zol and low Doc concen-
trations followed by a prolonged Zol exposure proved to
be the most effective combination. In particular, this
schedule produced an elevated synergistic interaction and
a strong decrease in cell viability. Conversely, the combi-
nation of Zol followed by simultaneous exposure to Zol
and Doc induced only a weak additive effect, which may
be a result of Zol triggering apoptosis directly in the G0/1
phase and leaving virtually no cells in G2/M, which is
known to be Doc's main target.
Drug concentrations and exposure times utilized in our
study were chosen on the basis of both literature data [19-
28] and results from preclinical investigations carried out
in our laboratory [29,30] to identify dosages and timing
that would have a significant impact on hormone-sensi-
tive prostate cancer cell survival. Our results suggest that
this therapeutic approach could be useful as first-line
treatment of hormone-sensitive prostate cancer. Further-
more, notwithstanding the obvious differences between
our experimental system and a clinical setting of meta-
static prostate cancer, the cell model (LNCaP) we used was
originally isolated from a metastatic lymph node [31] and
can therefore be considered fairly representative of hor-
mone-sensitive metastatic disease. This would seem to
suggest the potential clinical applicability of our results
for patients with hormone-sensitive metastatic prostate
cancer.
The two drugs induced mainly independent effects on
apoptosis and cell proliferation. In fact, low Doc concen-
trations produced a high cytostatic effect, probably linked
to cell cycle arrest, but induced a relatively low fraction of
apoptotic cells, whereas Zol exerted a predominantly high
cytotoxic and pro-apoptotic effect on the cell line. Despite
this apparent incongruence, sequential exposure to the
two-drug sequence caused a considerable increment in the
percentage of apoptotic cells, reaching values between 2-
and 6-fold higher than those observed after single drug
Apoptotic cells (%) measured by Ann-V assay in LNCaP line grown in normal medium (white bars), charcoal-stripped (c.s.) hor- mone-deprived medium (grey bars) and normal medium after taxane pre-treatment (black bars) Figure 4
Apoptotic cells (%) measured by Ann-V assay in LNCaP line grown in normal medium (white bars), charcoal-
stripped (c.s.) hormone-deprived medium (grey bars) and normal medium after taxane pre-treatment (black 
bars). Cells were analyzed after a 1-h exposure to Doc 0.01 μM followed by a 96- or 120-h w.o. (left histogram bars), after a 
96- or 120-h continuous exposure to Zol 100 μM (center histogram bars), and after exposure to the Doc-Zol combination 
(right histogram bars). The percentage of apoptosis in untreated cells never exceeded 10%. Error bars represent the mean 
standard deviation.Journal of Translational Medicine 2008, 6:43 http://www.translational-medicine.com/content/6/1/43
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pMEK, Mcl-1, p21 and active caspase-3 protein expression observed by western blot after exposure to different drug schedules Figure 5
pMEK, Mcl-1, p21 and active caspase-3 protein expression observed by western blot after exposure to different 
drug schedules. In the combination schedule, drug concentrations were the same as those used for single drug exposures.Journal of Translational Medicine 2008, 6:43 http://www.translational-medicine.com/content/6/1/43
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exposure, and further confirming the synergistic cytotoxic
effect.
We also evaluated drug activity in cells grown in hor-
mone-deprived medium, thus approximating the stand-
ard clinical setting in which prostate cancer patients are
treated with androgen deprivation therapy. Under these
conditions, the percentage of apoptotic cells after expo-
sure to various treatment schedules was similar to that
observed in cells grown in normal medium, indicating
that a hormone-deprived environment should not, in the-
ory, compromise the activity of chemotherapy. Moreover,
single drug or combination activity was maintained in
LNCaP cells pre-treated with low Doc concentrations. Our
results therefore suggest that treatment with low taxane
doses would not preclude response to conventional
docetaxel doses used in the clinical treatment of
advanced, hormone-refractory tumors.
Cell reactions to single drugs and their association were
paralleled by alterations in the expression of proteins
involved in cell proliferation and apoptosis. Zol treatment
generally induced a prolonged downregulation of both
pMEK, known to be involved in cell proliferation signal
transduction [8], and the anti-apoptotic protein, Mcl-1
[9]. Furthermore, the bisphosphonate did not cause any
major changes in p21 expression, known to be related to
cell cycle arrest and Doc resistance [32], and triggered the
activation of the pro-apoptotic caspase-3 only after a long
exposure. Conversely, low Doc concentrations induced a
less evident downregulation of pMEK, an upregulation of
Mcl-1 at the longest washout times, a clear increase in p21
expression, and a slight increase in the active form of cas-
pase-3. Following the synergistic drug sequence used in
our study, pMEK and Mcl-1 expression strongly decreased
and p21 expression was slightly downsized, whereas acti-
vated caspase-3 showed early and marked upregulation.
These results suggest that treatment with low Doc concen-
trations activates apoptotic processes, which, however,
may not be completed due to the concomitant triggering
of pMEK-, Mcl-1- and p21-mediated survival pathways.
Conversely, Zol seems to induce apoptosis and downreg-
ulate Doc-elicited anti-apoptotic mechanisms, bringing to
an end the cell death processes initiated by the taxane.
Targeting pathways that converge on complementary sig-
nalling cascades is a strategy worthy of being exploited
[33,34]. In agreement with this principle, our results dem-
onstrate that simultaneous MEK and Mcl-1 inhibition
induced by Zol, together with Doc-triggered apoptosis,
could be key objectives in the treatment of hormone-sen-
sitive prostate cancer.
The data reported in the present paper confirm those from
other preclinical studies on the efficacy of Zol and Doc-
Zol combinations [4,20,21] in the treatment of prostate
cancer cells. They also highlight the importance of the
schedule evaluated in hormone-sensitive cells using con-
centrations and exposures that could potentially occur in
a clinical setting. Furthermore, considering the metastatic
origin of the LNCaP cell line, our treatment option could
also prove valuable in the management of hormone-sen-
sitive metastatic cancer and in preventing the develop-
ment of bone metastases regardless of hormone
deprivation conditions, as suggested by Saad et al. [5].
Conclusion
In conclusion, although further research is needed to
widen our knowledge of the mechanisms underlying the
cytotoxic synergistic interaction and to explore other drug
schedules, the results from the present study suggest that,
under androgen deprivation conditions, low Doc doses in
concomitance with and followed by Zol could be a poten-
tially useful first-line treatment for hormone-sensitive
prostate cancer. This schedule would seem to be capable
of reducing the tumor cell population and of rapidly erad-
icating hormone-resistant cells present in hormone-
responsive tumors, without compromising the use of con-
ventional-dose Doc.
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